US$ 27.05
glp-1 libido Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it Are GLP-1 weight loss drugs
Description
Conflicting resultsneed for more transparent and reproducible research
In fact, meta-analyses in JAMA Psychiatry found no link between GLP-1s and psychiatric adverse eventsand some studies suggest lower rates of depressive symptoms in treated patients compared to placebo

GLP-1 receptor agonist lixisenatide protects against high free fatty acids-induced oxidative stress and inflammatory response

An interesting cross-talk between the glucagon-like peptide-1 receptor axis and angiotensin receptor pathway for modulation of renal sodium handling in obesity
